[go: up one dir, main page]

WO2009143281A3 - Compositions comprising c-met sirna and methods of use thereof - Google Patents

Compositions comprising c-met sirna and methods of use thereof Download PDF

Info

Publication number
WO2009143281A3
WO2009143281A3 PCT/US2009/044723 US2009044723W WO2009143281A3 WO 2009143281 A3 WO2009143281 A3 WO 2009143281A3 US 2009044723 W US2009044723 W US 2009044723W WO 2009143281 A3 WO2009143281 A3 WO 2009143281A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
met sirna
met
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/044723
Other languages
French (fr)
Other versions
WO2009143281A2 (en
Inventor
Frank Y. Xie
Xiaodong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silence Therapeutics PLC
Original Assignee
Intradigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corp filed Critical Intradigm Corp
Publication of WO2009143281A2 publication Critical patent/WO2009143281A2/en
Publication of WO2009143281A3 publication Critical patent/WO2009143281A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides nucleic acid molecules that inhibit c-Met expression. Methods of using the nucleic acid molecules are also provided.
PCT/US2009/044723 2008-05-20 2009-05-20 Compositions comprising c-met sirna and methods of use thereof Ceased WO2009143281A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5476808P 2008-05-20 2008-05-20
US61/054,768 2008-05-20

Publications (2)

Publication Number Publication Date
WO2009143281A2 WO2009143281A2 (en) 2009-11-26
WO2009143281A3 true WO2009143281A3 (en) 2010-03-11

Family

ID=40963274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044723 Ceased WO2009143281A2 (en) 2008-05-20 2009-05-20 Compositions comprising c-met sirna and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2009143281A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130023578A1 (en) * 2009-12-31 2013-01-24 Samyang Biopharmaceuticals Corporation siRNA for inhibition of c-Met expression and anticancer composition containing the same
WO2011130065A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2013064163A1 (en) * 2011-11-01 2013-05-10 Academisch Medisch Centrum Methylation markers for colorectal cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095622A2 (en) * 2004-03-26 2005-10-13 Van Andel Research Institute c-met siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL GROWTH, INVASION AND TUMORIGENICITY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095622A2 (en) * 2004-03-26 2005-10-13 Van Andel Research Institute c-met siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL GROWTH, INVASION AND TUMORIGENICITY

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARTIGIANI STEFANIA; CONROTTO PAOLO; FAZZARI PIETRO; GILESTRO GIORGIO F; BARBERIS DAVIDE; GIORDANO SILVIA; COMOGLIO PAOLO M; TAMAGN: "Plexin-B3 is a functional receptor for semaphorin 5A.", EMBO REPORTS JUL 2004, vol. 5, no. 7, July 2004 (2004-07-01), pages 710 - 714, XP002543077, ISSN: 1469-221X *
CHENG NIKKI; CHYTIL ANNA; SHYR YU; JOLY ALISON; MOSES HAROLD L: "Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.", CANCER RESEARCH 15 MAY 2007, vol. 67, no. 10, 15 May 2007 (2007-05-15), pages 4869 - 4877, XP002543069, ISSN: 0008-5472 *
HECHT MONICA; SCHULTE JOHANNES H; EGGERT ANGELIKA; WILTING JOERG; SCHWEIGERER LOTHAR: "The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness.", CARCINOGENESIS DEC 2005, vol. 26, no. 12, December 2005 (2005-12-01), pages 2105 - 2115, XP002543073, ISSN: 0143-3334 *
LEELAWAT KAWIN; LEELAWAT SURANG; TEPAKSORN PANADA; RATTANASINGANCHAN PANTHIP; LEUNGCHAWENG ANICHA; TOHTONG RUTAIWAN; SOBHON PRASER: "Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met.", THE JOURNAL OF SURGICAL RESEARCH NOV 2006, vol. 136, no. 1, November 2006 (2006-11-01), pages 78 - 84, XP002543071, ISSN: 0022-4804 *
MA PATRICK C; JAGADEESWARAN RAMASAMY; JAGADEESH SIMHA; TRETIAKOVA MARIA S; NALLASURA VIDYA; FOX EDWARD A; HANSEN MARK; SCHAEFER ER: "Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.", CANCER RESEARCH 15 FEB 2005, vol. 65, no. 4, 15 February 2005 (2005-02-15), pages 1479 - 1488, XP002543076, ISSN: 0008-5472 *
MAEDA AKINOBU; NAKASHIRO KOH-ICHI; HARA SHINGO; SASAKI TOYOKAZU; MIWA YOSHIHIRO; TANJI NOZOMU; YOKOYAMA MASAYOSHI; HAMAKAWA HIROYU: "Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 8 SEP 2006, vol. 347, no. 4, 8 September 2006 (2006-09-08), pages 1158 - 1165, XP002543072, ISSN: 0006-291X *
PURI NEELU; AHMED SALMAN; JANAMANCHI VARALAKSHMI; TRETIAKOVA MARIA; ZUMBA OSVALDO; KRAUSZ THOMAS; JAGADEESWARAN RAMASAMY; SALGIA R: "c-Met is a potentially new therapeutic target for treatment of human melanoma.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 APR 2007, vol. 13, no. 7, 1 April 2007 (2007-04-01), pages 2246 - 2253, XP002543070, ISSN: 1078-0432 *
TAKEUCHI HIROYA; KIM JOSEPH; FUJIMOTO AKIHIDE; UMETANI NAOYUKI; MORI TAKUJI; BILCHIK ANTON; TURNER ROD; TRAN ANDY; KUO CHRISTINE;: "X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 NOV 2005, vol. 11, no. 21, 1 November 2005 (2005-11-01), pages 7621 - 7628, XP002543074, ISSN: 1078-0432 *
ZHANG SHENG-ZHOU; PAN FEI-YAN; XU JIAN-FENG; YUAN JUN; GUO SHI-YING; DAI GU; XUE BIN; SHEN WEI-GAN; WEN CHUAN-JUN; ZHAO DONG-HONG;: "Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo.", MOLECULAR CANCER THERAPEUTICS OCT 2005, vol. 4, no. 10, October 2005 (2005-10-01), pages 1577 - 1584, XP002543075, ISSN: 1535-7163 *

Also Published As

Publication number Publication date
WO2009143281A2 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use
AU2017248555B2 (en) Closed nucleic acid structures
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
WO2011072099A3 (en) Compositions and methods comprising protease variants
HK1205751A1 (en) Conjugates, particles, compositions, and related methods
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
WO2009077471A3 (en) Azolylmethyloxiranes, use thereof and agents containing the same
WO2010011331A3 (en) Compositions and methods related to sirt1 function
WO2009114724A3 (en) COMPOSITIONS COMPRISING NUCLEAR FACTOR-KAPPA B (NF-ĸB) SIRNA AND METHODS OF USE
WO2009111586A3 (en) Autonomous in vitro evolution
WO2007106915A3 (en) Antibodies to egfl7 and methods for their use
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
WO2009143371A3 (en) COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
WO2011140334A3 (en) Compounds, methods of making or identifying compounds, and uses thereof
WO2009143277A3 (en) Compositions comprising hscn9a sirna and methods of use thereof
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same
WO2009152387A3 (en) Compositions comprising cmyc sirna and methods of use thereof
EP2421880A4 (en) COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF NUCLEIC ACID
WO2009143281A3 (en) Compositions comprising c-met sirna and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09751509

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09751509

Country of ref document: EP

Kind code of ref document: A2